A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

November 30, 2027

Conditions
Advanced Solid TumorsBreast CancerNon Small Cell Lung Cancer
Interventions
DRUG

YL202 for injection; Toripalimab injection

"Part 1: YL202 and Toripalimab will be administered intravenously.~Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined.~Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab"

DRUG

YL202 for injection; Furmonertinib Mesilate Tablets

"Part 2: YL202 will be administered intravenously,Furmonertinib Mesilate Tablets will be administered orally.~Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined.~Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate."

Trial Locations (20)

30013

NOT_YET_RECRUITING

Shanxi Cancer Hospital, Taiyuan

71051

NOT_YET_RECRUITING

Affiliated Hospital Of Hebei University, Baoding

110042

NOT_YET_RECRUITING

Liaoning cancer hospital &institute, Shenyang

116001

NOT_YET_RECRUITING

Affiliated Zhongshan Hospital Dalian University, Dalian

150081

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

201321

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

210029

NOT_YET_RECRUITING

Jiangsu Province Hospital(The First Affiliated Hospital With Nanjing Medical University, Jiangsu Women And Children Health Hospital), Nanjing

230001

NOT_YET_RECRUITING

Anhui Provincial Hospital(The First Affiliated Hospital of Ustc), Hefei

250117

NOT_YET_RECRUITING

Affiliated Zhongshan Hospital Dalian University, Jinan

300300

NOT_YET_RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

350014

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fuzhou

415000

NOT_YET_RECRUITING

The First People's Hospital of Changde City, Changde

441138

NOT_YET_RECRUITING

Xiangyang Central Hospital, Xiangyang

455100

NOT_YET_RECRUITING

Anyang Cancer Hospital, Anyang

471023

NOT_YET_RECRUITING

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

510555

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

514031

NOT_YET_RECRUITING

Meizhou People's Hospital(Huangtang Hospital)Meizhou Academy of Medical Sciences, Meizhou

530028

NOT_YET_RECRUITING

Ghang xi Medical University Cancer Hospital, Nanning

610072

NOT_YET_RECRUITING

Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital, Sichuan

Unknown

NOT_YET_RECRUITING

Jiangxi Cancer Hospital, Nanchang

All Listed Sponsors
lead

MediLink Therapeutics (Suzhou) Co., Ltd.

INDUSTRY

NCT07169994 - A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter